ASC4KIDS-2 (Chronic myeloid leukemia)
Clinical study to evaluate the safety and efficacy of the drug asciminib in pediatric and adolescent participants who are recently newly diagnosed or previously treated and who have Philadelphia positive Chronic Myeloid Leukemia (CML) in Chronic Phase with or without known T315I mutation.
Recruiting
Who can enter
Children who are recently newly diagnosed with chronic myeloid leukemia (CML) or who have been previously treated for CML
Age: 1 year to <18 year
Goal
The goal of this study is to learn more about the effects of asciminib in children and adolescents with CML. We are testing asciminib in children and adolescents with chronic myeloid leukemia who have recently been diagnosed or who have been treated previously.
Background
At this moment, there is no suitable treatment specifically for children with Philadelphia-positive chronic myeloid leukemia in the chronic phase, with or without a known T315I mutation. That is why we want to investigate whether this treatment with asciminib is effective.
Asciminib is a so-called tyrosine kinase inhibitor. These are medicines that target the BCR-ABL1 protein. This protein is produced by the BCR-ABL gene. BCR-ABL1 stimulates the growth of leukemia cells. Asciminib binds to a specific part of the BCR-ABL1 protein and thereby blocks its function. As a result, the growth of the leukemia cells can be stopped.
We want to determine how asciminib works and how safe it is.
Participation in the study lasts approximately 4 to 7 years. During the study, several additional tests and assessments will be performed that differ from standard care. For example, a bit more blood or bone marrow will be collected. We will also perform electrocardiograms (ECGs) more frequently.
The drug is not yet approved for the treatment of CML in children. However, it has already been approved as a treatment for adults with CML.
In order to participate in a study please refer to your/your child’s doctor.
Last reviewed
August 24, 2026
Study details
- Study details
Official title
A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation.Cancer type
Chronic Myeloid Leukemia (CML)Phase
2Maximum number of patients
50, of whom 1 is expected to participate in the NetherlandsStart date
August 24, 2026Status
OpenLocal principal investigator
Dr. Maaike LuesinkSponsor
Novartis Pharma B.V.Approval
The study of this new treatment has been reviewed by an accredited medical research ethics committee: Stichting BEBO located in Assen. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO.Trial registry number
EU Clinical Trials: 2025-522138-29
ClinialTrials.gov: NCT07354074
The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.